|
[1]戚中田.丙型肝炎病毒感染与治疗药物[J].临床肝胆病杂志, 2011, 27 (1) :15-18.
|
|
[2]Pizarro C, Venegas M, Hola K, et al.Results of treatmentwith peginterferon plus ribavirin in patients with chronic hepa-titis[J].Rev Med Chil, 2011, 139 (6) :704-709.
|
|
[3]Toyoda H, Kumada T.Incidence of hepatocellular carcinomaand response to interferon therapy in HCV-infected pa-tients:effect of factors associated with the therapeutic re-sponse and incidence of HCC[J].Liver Int, 2012, 32 (16) :1029-1031.
|
|
[4]Sherman KE.Advanced liver disease:what every hepatitis Cvirus treater should know[J].Top Antivir Med, 2011, 19 (3) :121-125.
|
|
[5]Rubín A, Aguilera V, Berenguer M.Liver transplantation andhepatitis C[J].Clin Res Hepatol Gastroenterol, 2011, 35 (12) :805-812.
|
|
[6]European Association for the Study of the Liver.EASL ClinicalPractice Guidelines:Management of hepatitis C virus infec-tion[J].J Hepatol, 2011, 55 (2) :245-264.
|
|
[7]Berger A.Antiviral treatment of chronic hepatitis C[J].MedMonatsschr Pharm, 2012, 35 (2) :55-60.
|
|
[8]Van Gulick JJ, Lamers MH, Drenth JP.Hepatitis C virus in-fection management in 2012[J].Panminerva Med, 2012, 54 (1) :1-9.
|
|
[9]Liu J, Shi S, Zhuang H, et al.Recent advance in antiviraldrugs for hepatitis C[J].Zhong Nan Da Xue Xue Bao Yi XueBan, 2011, 36 (11) :1025-1036.
|
|
[10]Fried MW, Shiffman ML, Reddy KR, et al.Peginterferon al-fa-2a plus ribavirin for chronic hepatitis C virus infection[J].N Engl J Med, 2002, 347 (13) :975-982.
|
|
[11]Tao J, Liu J, Pu D, et al.Efficacy of interferon alpha withribavirin for treatment of chronic Hepatitis C[J].ZhonghuaGan Zang Bing Za Zhi, 2011, 19 (9) :683-5.
|
|
[12]Yoshida H, Arakawa Y, Sata M, et al.Interferon therapyprolonged life expectancy among chronic hepatitis C patients[J].Gastroenterology, 2002, 123 (2) :483-491.
|
|
[13]Poynard T, McHutchison J, Manns M, et al.Impact of pe-gylated interferon alfa-2b and ribavirin on liver ibrosis in pa-tients with chronic hepatitis C[J].Gastroenterology, 2002, 122 (5) :1303-1313.
|
|
[14]Benvegnu L, Chemello L, Noventa F, et al.Retrospective a-nalysis of the effect of interferon therapy on the clinical out-come of patients with viral cirrhosis[J].Cancer, 1998, 83 (5) :901-909.
|
|
[15]Di Marco V, Almasio PL, Ferraro D, et al.Peg-interferon a-lone or combined with ribavirin in HCV cirrhosis with portalhypertension:a randomized controlled trial[J].J Hepatol, 2007, 47 (4) :484-491.
|
|
[16]Iacobellis A, Perri F, Valvano MR, et al.Long-term outcomeafter antiviral therapy of patients with hepatitis C virus infectionand decompensated cirrhosis[J].Clin Gastroenterol Hepatol, 2011, 9 (3) :249-253.
|
|
[17]Iacobellis A, Siciliano M, Perri F, et al.Peginterferon alfa-2b and ribavirin in patients with hepatitis C virus and decom-pensated cirrhosis:a controlled study[J].J Hepatol, 2007, 46 (2) :206-212.
|
|
[18]Everson GT, Trotter J, Forman L, et al.Treatment of ad-vanced hepatitis C with a low accelerating dosage regimen ofantiviral therapy[J].Hepatology, 2005, 42 (2) :255-262.
|
|
[19]Crippin JS, McCashland T, Terrault N, et al.A pilot study ofthe tolerability and eficacy of antiviral therapy in hepatitis C vi-rus-infected patients awaiting liver transplantation[J].LiverTranspl, 2002, 8 (4) :350-355.
|
|
[20]Bacon BR, Khalid O.New therapies for hepatitis C virus in-fection[J].Mo Med, 2011, 108 (4) :255-259.
|
|
[21]Peck-Radosavljevic M, Wichlas M, Homoncik-kraml M, et al.Rapid suppression of hematopoiesis by standard or pe-gylated interferon-alpha[J].Gastroenterology, 2002, 123 (1) :141-151.
|
|
[22]Di Marco V, Almasio PL, Ferraro D, et al.Peg-interferon a-lone or combined with ribavirin in HCV cirrhosis with portalhypertension:a randomized controlled trial[J].J Hepatol, 2007, 47 (4) :484-491.
|
|
[23]Vezali E, Aghemo A, Colombo M.A review of the treatmentof chronic hepatitis C virus infection in cirrhosis[J].Clin T-her, 2010, 32 (13) :2117-2138.
|
|
[24]Van Gulick JJ, Lamers MH, Drenth JP.Hepatitis C virus in-fection management in 2012[J].Panminerva Med, 2012, 54 (1) :1-9.
|
DownLoad: